<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333187</url>
  </required_header>
  <id_info>
    <org_study_id>MMM 02 study / RuxoAlloStudy</org_study_id>
    <nct_id>NCT03333187</nct_id>
  </id_info>
  <brief_title>Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability</brief_title>
  <official_title>Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CTC North (CRO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will be a multicenter, prospective phase II-study comparing efficacy of
      allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3
      months Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and
      will continue to receive Ruxolitinib.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, prospective phase II-study compares efficacy of allogeneic SCT
      for patients with myelofibrosis who have a suitable stem cell donor after a 3 months
      Ruxolitinib induction therapy with patients who lack a suitable stem cell donor and will
      continue to receive Ruxolitinib.

      In this study will further assess and compare the safety and efficacy of study treatments/
      induction therapy in both study arms on spleen reduction, improvement of constitutional
      symptoms, QOL, toxicity, fibrosis regression, development of GvHD as well as chimerism,
      engraftment, relapse incidence, disease related mortality, outcome and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2016</start_date>
  <completion_date type="Anticipated">March 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment A (only with a suitable stem cell donor):
Allogeneic SCT after 3 months of Ruxolitinib induction therapy
Treatment B:
Ruxolitinib continuous therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Event free survival at 3 years after allogeneic SCT compared to Ruxolitinib continuous therapy in patients without a suitable donor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Speen reduction</measure>
    <time_frame>3 months</time_frame>
    <description>Spleen reduction after 3 months Ruxolitinib induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of constitutional symptoms</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement of constitutional symptoms (Loose of weight and night sweat) after 3 months Ruxolitinib induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of bone marrow fibrosis</measure>
    <time_frame>3 months</time_frame>
    <description>Improvement of bone marrow fibrosis after 3 months of Ruxolitinib induction therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft-versus-host disease</measure>
    <time_frame>Day +100 after allogeneic SCT</time_frame>
    <description>Incidence of acute graft-versus-host disease on Day +100 after allogeneic SCT according to the Glucksberg scale revised by Przepiorka</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic graft-versus-host disease</measure>
    <time_frame>1, 2 and 3 years after allogeneic SCT</time_frame>
    <description>Incidence of chronic graft-versus-host disease according to the NIH consensus criteria of Filipovich et al. at 1, 2 and 3 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of Ruxolitinib</measure>
    <time_frame>till 3 years</time_frame>
    <description>Toxicity of Ruxolitinib scored according to NCI CTCAE, Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of conditioning therapy</measure>
    <time_frame>till 3 years</time_frame>
    <description>Toxicity of conditioning therapy scored according to NCI CTCAE, Version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Cumulative incidence of relapse at 3 years after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-related mortality</measure>
    <time_frame>3 years</time_frame>
    <description>Disease-related mortality at 3 years after allogeneic SCT and Ruxolitinib continuous therapies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapsed mortality</measure>
    <time_frame>1 and 3 years</time_frame>
    <description>Non-relapsed mortality at 1 and 3 years after allogeneic SCT and Ruxolitinib continuous therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate</measure>
    <time_frame>3 years</time_frame>
    <description>Discontinuation rate at 3 years after Ruxolitinib continuous therapy (End of study)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Sorror Risk Score</measure>
    <time_frame>at baseline</time_frame>
    <description>Evaluation of Sorror Risk Score on outcome after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism on relapse</measure>
    <time_frame>30d, 100d, 180 d, 1 year, 2 years and 3 years</time_frame>
    <description>Impact of chimerism on relapse incidence after allogeneic SCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow fibrosis regression</measure>
    <time_frame>30d, 100d, 1 year, and 3 years</time_frame>
    <description>Evaluation of bone marrow fibrosis regression after allogeneic SCT at 30d, 100d, 1 year, and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow fibrosis regression</measure>
    <time_frame>30d, 100d, 1 year and 3 years</time_frame>
    <description>Evaluation of bone marrow fibrosis regression after Ruxolitinib continuous therapy at 30d, 100d, 1 year and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (FACT-BMT)</measure>
    <time_frame>baseline, at transplantation, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (MPN-SAF-TSS)</measure>
    <time_frame>baseline, at transplantation, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at transplantation, and after transplantation at 6m, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (FACT-BMT)</measure>
    <time_frame>baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Evaluation of QOL (FACT-BMT) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of QOL (MPN-SAF-TSS)</measure>
    <time_frame>baseline, confinement to Ruxolitinib continous therapy, +180d, +1 year, +2 years and +3 years</time_frame>
    <description>Evaluation of QOL (MPN-SAF-TSS) before Ruxolitinib induction therapy (= baseline), at confinement to Ruxolitinib continuous therapy and after confinement at 6 months, 1 year, 2 years and 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival at 3 years after allogeneic SCT compared to Ruxolitinib continuous therapy in patients without a suit-able donor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Bone Marrow Fibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Allogeneic Stem cell Transplantation after 3 months of Ruxolitinib induction therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Ruxolitinib continuous therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic stem cell transplantation</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib continuous therapy</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Symptomatic primary myelofibrosis or myelofibrosis post polycythaemia vera or
             essential thrombocythemia stage intermediate 2- or high-risk according to IPSS or
             DIPSS [46] or intermediate 1-risk with high risk cytogenetics, other than normal
             karyotype, sole del 20q, del 13q, or sole+9, or transfusion-dependency

          2. Patients age: 18 - 70 years at time of inclusion (female and male)

          3. Patients understand and voluntarily sign an informed consent form

          4. Platelet count ≥ 50 x 109/L

          5. No prior Ruxolitinib treatment

          6. ECOG ≤ 2

        Exclusion Criteria:

          1. Severe renal, hepatic, pulmonary or cardiac disease, such as:

               -  Total bilirubin, SGPT or SGOT &gt; 3 times upper the normal level

               -  Left ventricular ejection fraction &lt; 30 %

               -  Creatinine clearance &lt; 30 ml/min

               -  DLCO &lt; 35 % and/or receiving supplementary continuous oxygen

          2. Positive serology for HIV

          3. Pregnant or lactating women (positive serum pregnancy test)

          4. Age &lt; 18 and ≥ 71 years.

          5. Uncontrolled invasive fungal infection at time of screening (baseline)

          6. Serious psychiatric or psychological disorders

          7. Participation in another study with ongoing use of unlicensed investigational product
             from 28 days before study enrollment

          8. Transformation to AML
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolaus Kröger, Prof. Dr.</last_name>
    <phone>+49(0)40-7410-55864</phone>
    <email>n.kroeger@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine Wolschke, Dr.</last_name>
    <phone>+49(0)40-7410-54188</phone>
    <email>wolschke@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinkum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Jost, PD Dr.</last_name>
      <email>ejost@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Edgar Jost, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Crysandt, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herrad Baurmann, Dr.</last_name>
      <email>herrad.baurmann@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Herrad Baurmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Fuhrmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <email>dominik.wolf@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Dominik Wolf, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin Mayer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guido Kobbe, Prof. Dr.</last_name>
      <email>Kobbe@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Guido Kobbe, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Schröder, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Göthert, Dr.</last_name>
      <email>Joachim.Goethert@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Joachim Göthert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Novotny, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kiehl, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Olaf Hopfer, Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Olaf Hopfer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Fellas</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haifa Kathrin Al-Ali, PD Dr.</last_name>
      <email>haifa.al-ali@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Haifa Kathrin Al-Ali, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadja Jäckel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
      <phone>+49-40-7410-55864</phone>
      <email>n.kroeger@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Marion Heinzelmann</last_name>
      <phone>+49-40-7410-54188</phone>
      <email>mheinzel@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolaus Kroeger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Wolschke, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inken Hilgendorf, PD Dr.</last_name>
      <email>Inken.Hilgendorf@med.uni-jena.de</email>
    </contact>
    <investigator>
      <last_name>Inken Hilgendorf, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nils Winkelmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dietger Niederwieser, Prof. Dr.</last_name>
      <email>Dietger.Niederwieser@medizin.uni-leipzig.de</email>
    </contact>
    <investigator>
      <last_name>Dietger Niederwieser, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadja Jäkel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Wagner, Dr.</last_name>
      <email>eva.wagner@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Eva Wagner, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Kindler, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Klein, PD Dr.</last_name>
      <email>Stefan.Klein@medma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Klein, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Reiter, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Burchert, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Burchert, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Sohlbach, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johannes Wesling Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Griesshammer, Prof. Dr.</last_name>
      <email>martin.griesshammer@muehlenkreiskliniken.de</email>
    </contact>
    <investigator>
      <last_name>Martin Griesshammer, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans-Joachim Tischler, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <email>Matthias.Stelljes@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Eva Schmidt, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Schäfer-Eckart, Dr.</last_name>
      <email>Kerstin.Schaefer-Eckart@klinikum-nuernberg.de</email>
    </contact>
    <investigator>
      <last_name>Kerstin Schäfer-Eckart, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Knut Wendelin, Dr,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kaufmann, Dr.</last_name>
      <email>Martin.Kaufmann@rbk.de</email>
    </contact>
    <investigator>
      <last_name>Martin Kaufmann, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Vöhringer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Bethge, Prof. Dr.</last_name>
      <email>Wolfgang.Bethge@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Bethge, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Faul, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinkum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstanze Döhner, Prof. Dr.</last_name>
      <email>Konstanze.Doehner@uniklinik-ulm.de</email>
    </contact>
    <investigator>
      <last_name>Konstanze Döhner, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frank Stegelmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis, Myeloproliferative Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

